PTO/SB/05 (06-03)

Approved for use through 07/31/2003. OMB 0651-0032

U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION

Attorney Docket No.	21554	
First Inventor	Alexander Mayweg	
Title	Novel CB 1 Rec ptor Ir	
Express Mail Label No.	EL267099223US	

TRANSMITTAL	Title	Novel CB 1 Rec ptor Ir
only for new nonprovisional applications under 37 CFR 1.53(b))	Express Mail Label No.	EL267099223US
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO:	Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450
1.  Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27.  3.  Specification [Total Pages 191]   Descriptive title of the invention	Computer Program  8. Nucleotide and/or Ami (if applicable, all neces a. Computer Ro b. Specification i. CD-RO ii. Paper c. Statements  ACCOMPANYI  9. Assignment Pap 10. 37 CFR 3.73(b) (when there is a 11. English Translat 12. Information Disc Statement (IDS) 13. Preliminary Ame 14. Return Receipt I (Should be spec) 15. Certified Copy o (if foreign priority)	no Acid Sequence Submission sary) eader Form (CRF) in Sequence Listing on:  DM or CD-R (2 copies); or  verifying identity of above copies  NG APPLICATION PARTS  Deers (cover sheet & document(s)) Statement Power of Attorney clion Document (if applicable) closure Copies of IDS citations endment Postcard (MPEP 503) iffically itemized) if Priority Document(s)
1.63(d)(2) and 1.33(b).  6. Application Data Sheet. See 37 CFR 1.76	(b)(2)(B)(i). Appl or its equivalent. Other:Declara	licant must attach form PTO/SB/35
18. If a CONTINUING APPLICATION, check appropriate box, and sup specification following the title, or in an Application Data Sheet under 3  Continuation  Divisional  Continuation:  Examiner  For CONTINUATION OF DIVISIONAL APPS only; The entire disclosure of the 5b, is considered a part of the disclosure of the accompanying continuation The incorporation can only be relied upon when a portion has been inadver	7 CFR 1.76:  tion-in-part (CIP) of prior a  Art Unit: e prior application, from which a or divisional application and is	application No.:application No.: supplied under Box shereby incorporated by reference.
19. CORRESPON	DENCE ADDRESS	
Customer Number: 00151	OR 🗆	Correspondence address below
Name		
Address		
City	State	Zip Code
	elephone	Fax
Name (Print/Type) Lyman H. Smith	Registration No. (Attorney/A	
Signature		Date 12/22/2003

This collection of information is required by 37 CFR 9.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Director of the United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

Hoffmann-La Roche Inc. 340 Kingsland Street Nutley, NJ 07110 Case Docket 21554 December 22, 2003

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is the patent application of

Inventor(s):

Alexander Mayweg, Hans Peter Marty, Werner Mueller, Robert Narquizian, Werner

Neidhart, Philippe Pflieger, and Stephan Roever

For: NOVEL CB 1 RECEPTOR INVERSE AGONISTS

## 1. The fee has been calculated as shown below:

CLAIMS				
FOR	NO. FILED	NO. EXTRA	RATE	FEE
TOTAL CLAIMS	38 - 20	18	x \$18	\$324
INDEP. CLAIMS	3 - 3	0	x \$86	\$0
MULTIPLE DE	EPENDENT CLAI	MS PRESENTED	+ \$290	
		BASIC FEE	-	\$770
			TOTA	L \$1,094

Please charge Deposit Account No. 08-2525 in the amount noted above.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 08-2525, including those under 37 C.F.R. § 1.16 and 1.17. This sheet is provided in duplicate.

Continue to address all communications to:

DEPOSIT ACCOUNT NO. 08-2525

OUR ORDER NO. <u>5256</u>

George W. Johnston Hoffmann-La Roche Inc. 340 Kingsland Street Nutley, NJ 07110

Agent for Applicant(s)

Lyman H. Smith (Reg. No. 44,342)

137418



## Certification under 37 CFR 1.10

I hereby certify that this form and all documents cited on this form are being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number:

	EL267099223US
addressed to:	Commissioner for Patents
	P.O. Box 1450
	Alexandria, VA 22313-1450
on <u>Decem</u>	ber 22, 2003
	Date
	Let Flip Me Signature
	Jill Filippone
	Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Papers Submitted for Case Docket 21554: Patent Application Transmittal Form, Application Data Sheet, Fee Transmittal Form, Specification, Declaration, Information Disclosure Statement, Form 1449